

Sustainability of Pulmonary Rehab Gains

NCT02241733

8/13/2019

Introduction. Chronic obstructive pulmonary disease (COPD) is characterized by progressive airway obstruction and limited exercise tolerance.^{1,2} A major determinant of limited exercise tolerance in COPD is the development of exercise-induced dynamic hyperinflation.³ The severity of exercise-induced dynamic hyperinflation can be reduced using several strategies⁴ including a novel breathing-retraining technique that we developed.⁵ By combining this technique with exercise-training, patients with COPD can achieve greater improvements in symptoms, functional status, and quality of life than with exercise-training alone.⁶⁻⁸

A crucial aspect of any pulmonary rehabilitation program is the maintenance of the early benefits of rehabilitation over the long-term.^{9,10} Unfortunately, in most patients those benefits significantly decrease six to twelve months after traditional rehabilitation programs have ended,^{9,11,12} and nearly disappear thereafter.¹³ The inability to maintain the benefits of traditional rehabilitation over time exposes patients to an increased risk of functional decline, exacerbations, hospitalizations, and worse quality of life.^{9,12,14,15} The few patients in whom the benefits of traditional pulmonary rehabilitation persist over time are those who achieve high self-efficacy.¹³

Cognizant of these findings, we explored whether self-efficacy was affected by our breathing technique in 64 COPD patients undergoing rehabilitation.⁵ In that study, self-efficacy (quantified in terms of mastery over breathing) was greater after exercise-training plus breathing-retraining than after exercise-training alone.⁵ This observation raises the possibility that COPD patients undergoing rehabilitation programs where breathing-retraining is combined to traditional exercise-training may maintain the beneficial effects of rehabilitation for a longer time than patients undergoing traditional exercise alone. Accordingly, we propose to test the hypothesis that in COPD patients, improvements in exercise duration on a constant-load treadmill test will be greater after completing 12-weeks of breathing-retraining plus treadmill exercise followed by a 42-week adherence-intervention program (one year total) than after completing 12-weeks of treadmill exercise alone followed by a 42-week adherence-intervention program. The adherence-intervention will consist of weekly phone calls and monthly 'booster' visits to reinforce both exercise and, for the breathing-retraining group, breathing training. In addition, we propose to study potential mechanisms that can affect long-term sustainability of the gains achieved through pulmonary rehabilitation.

Hypothesis/Research Questions

Primary

H₁ In patients with COPD, improvements in exercise duration on a constant-load treadmill test will be greater after completing 12 weeks of breathing-retraining plus treadmill exercise-training followed by a 42-week adherence-intervention program (one year total) than after completing 12 weeks of treadmill exercise-training alone followed by a 42-week adherence-intervention program (one year total).

Secondary

H₂ One year after randomization, reductions in exercise-induced dynamic hyperinflation during a constant-load treadmill test will be greater in the breathing-retraining group than in the exercise-alone group.

H₃ One year after randomization, improvements in the 6-minute walk distance will be greater in the breathing-retraining group than in the exercise-alone group.

H₄ One year after randomization, improvements in perceived mastery over breathing will be greater in the breathing-retraining group than in the exercise-alone group.

General Overview of Design. The proposed study has been designed as a randomized, controlled clinical trial. After completing baseline testing, patients will be randomized to one of two groups: breathing-retraining plus exercise-training or exercise-training alone. We did not include a non-treatment group as it has been clearly demonstrated that patients randomized to a non-treatment group (no exercise-training) experience no significant improvements in exercise capacity.^{12,16}

Sample Size Calculation. Sample size calculations for the current proposal are based on two considerations. First, in our previous investigation⁶ we observed that the mean exercise endurance 6 weeks after the completion of training was 7.0 min greater with exercise plus breathing-retraining than with exercise alone. When the analysis was restricted to those patients who developed exercise-induced dynamic hyperinflation, the difference was 8.27 min. Second, due to greater gains in mastery over breathing with exercise plus breathing-retraining than with exercise alone,⁴⁷ we expect that the difference in exercise endurance between the two groups will widen over time – i.e., we expect that the breathing-retraining group will better maintain the benefits of rehabilitation than the exercise-alone group. Based on these considerations we conservatively estimate that the difference in exercise duration between the groups at 12 months will be 8.27 minutes with a pooled standard deviation of 13.7 min (effect size = .60).

This means that to achieve 85% power, 100 patients are needed (50 in each group) using two-sample t-test ($\alpha = .05$).

According to the local IRB, enrollment is the equivalent to a patient signing an informed consent. In our three latest studies,^{6,7,84} 30-46% of patients who signed the informed consent (i.e., enrollees) did not meet PFT criteria or did not qualify for other reasons. Accordingly, to have complete data on 100 patients while accounting for attrition due to disqualifying conditions, lack of exercise-induced dynamic hyperinflation, and short-term and long-term attrition, we plan to ‘enroll’ 250 patients (i.e., signed informed consent) and to ‘randomize’ 140 of them.

Recruitment. Patients with moderate-to-severe COPD, ≥ 40 years of age, will be recruited from the outpatient Pulmonary Medicine Service at the Hines VA (**Table 1**). No patient will be excluded based on gender or ethnicity. About 9 patients per month will be ‘enrolled’ with 5 of them being ‘randomized’.

Screening and Baseline

Testing. Proposed study participants will be screened for eligibility and written informed consent will be obtained. All testing and training will take place at Hines VAH’s Physical Performance Research Laboratory. During screening, patients will be asked about their medical history and medication use. This will be followed by physical examination, pulmonary function testing and completion of quality of life/dyspnea questionnaires. Then, patients will undergo an incremental-load

Table 1. Study Inclusion and Exclusion Criteria

Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none"> ≥ 40 yr of age FEV₁ $\leq 70\%$ FEV₁/FVC $< 70\%$ RV/TLC $\geq 120\%$ mean SpO₂ $\geq 90\%$ at peak exercise (w/ or w/o O₂) Inspiratory capacity decline of $>0.15L$ from rest to peak exercise 	<ul style="list-style-type: none"> Respiratory infection/exacerbation within the previous four weeks Exercise limiting heart disease (+ stress test or other indicators of heart disease or complaints of angina during the stress test) Primary asthma Congestive heart failure (New York Heart Association Class III or IV) Exercise-limiting peripheral arterial disease (stops exercise due to intermittent claudication) Stops exercise due to arthritic pain in the knee or hips (self-report) Inability to walk on the treadmill Pregnancy Any unforeseen illness or disability that would preclude exercise testing or training Participation in a formal exercise program within the previous 12 weeks

treadmill test. Thereafter, eligible patients will perform the baseline tests⁷ that include two constant-load treadmill tests, functional assessment of the respiratory muscles and quadriceps, quadriceps ultrasonography, physical activity monitoring and 6-min walk test. After the baseline testing is completed and study criteria are met, patients will be randomized to breathing-retraining plus exercise-training or to exercise-training alone.

Randomization will be computer-generated with permuted blocks with random block sizes. This strategy is intended to preserve balance in the randomization of patients to maintain unpredictability of the treatment assignments. Group assignment will be managed by the Hines Cooperative Studies Program Coordinating Center (CSPCC). When a patient is ready for randomization, we will contact the CSPCC to receive the randomization designation. To maintain testing integrity, one Co-PI will supervise patient testing and will be blinded to group assignment. When data are reviewed, the data will be void of any identifiers.

Exercise Prescription (All patients). Ambulation is a critical element to achieve adequate quality of life and independence. Accordingly, the primary mode of training will consist of ambulation on a treadmill. An individualized treadmill exercise prescription (interval training)^{34,36,89} will be prepared for each patient. This prescription will specify exercise intensity, duration of exercise intervals, duration of recovery intervals, and number of repetitions). During training, patients will progress through six levels of exercise intensity.⁹⁰ At ‘Level 1’, patients will exercise for a total of 25 min with 5 min of aerobic exercise at workloads equivalent to 60, 65, 70, 75 and 80% of VO_{2peak}. By the time patients progress to ‘Level 6’, they will complete a total of 50 min of aerobic exercise, with 35 min of training at 80 and 85% of VO_{2peak}. Rest periods between exercise intervals will be based on individual recovery patterns.⁷

All training sessions will also include progressive upper and lower body resistance exercises.⁷ Upper body resistance exercises will be carried out using rubber bands (TheraBand™), light hand weights and a Series II 8400 Schwinn Strength system.⁷ Lower body resistance exercises will be carried out using a LifeFitness leg curl, leg extension and leg press.⁴⁵ Patients will complete upper body exercises that recruit accessory muscles of respiration⁷ and lower body exercises that recruit muscles of ambulation. Upper and lower body resistance training will include 6-8 exercises (e.g., triceps extensions, lateral arm raises, leg press), it will be progressive (i.e., bands with greater resistance and heavier weights will be used as

patients' strength improves), and it will be completed in two sets of 12-15 repetitions per exercise.⁷ Patients will be instructed to avoid breath-holding during resistance exercise training.

All patients will exercise 3 times weekly for approximately 25-50 min of aerobic training and approximately 15 min of resistance training. To enhance self-efficacy for exercise during activities of daily living and mirror "real-life" home exercise, two exercise sessions during the last two weeks of training will take place outside of the lab (i.e., in the hallways or outdoors). During these sessions, the patient and trainer will problem solve real-life issues such as using perceived severity of exertion and perceived severity of breathless to gauge exercise intensity outside of the lab and, for the breathing-retraining group, practice slow breathing without the computer feedback. During testing and training, supplemental oxygen will be administered as needed to maintain SpO₂ ≥90%.

Exercise-Training. For all patients, training sessions will include a warm-up period, an interval training period, and a cool down period.⁷ Before, during and after training, heart rate, blood pressure, perceived severity of exertion and perceived severity of dyspnea (Borg ratio scale) will be recorded.⁷ Patients will receive instructions on how to use the Borg scale.⁷ The *Level* of exercise intensity will be based on protocol guidelines. Patients will complete at least two training sessions at each *Level* before progressing to the next *Level*.⁷ This progression will be based on rating of dyspnea (consistent ratings < 3 [moderate dyspnea]) and/or reduction in the duration of rest periods between exercise intervals.

Breathing-Retraining. Breathing-retraining will be conducted with the same strategy we successfully used in our previous studies.⁶⁻⁸ Patients will breathe through a pneumotachometer interfaced to a computer. Inhalation (T_I) and exhalation times (T_E) will be displayed on the computer's screen as moving horizontal bars. T_I and T_E goals will be shown as "targets" on the screen. These goals, and thus, respiratory frequency goals will be based on the breathing pattern recorded during the baseline incremental-load test.⁶⁻⁸ During inhalation, the bar on the computer screen will move to the left of the screen; during exhalation, it will move to the right. Patients are given a score ("hit" or "miss") with each breath. If at any time during training the patient is not able to hit the exhalation and inhalation targets at least 85% of the time, the respiratory rate will be increased by 1 breath/min increments until the patient can consistently "hit" the targets. When the patient is again able to hit the targets at least 85% of the time, the breathing-retraining parameters will be returned to levels corresponding to the goals of respiratory pattern for the given level of exercise. To avoid a potential placebo effect (i.e., desensitization to exercise-induced dyspnea as a result of being distracted by the computer screen), patients in the exercise-only group will train while watching scenic venues on the computer screen.

Adherence-Intervention Program. Following the 12 weeks of supervised training, all patients will participate in the adherence-intervention program developed. This adherence intervention program consists of three elements: use of pedometer, weekly motivational phone interviews and monthly 'booster' structured rehabilitation session in the lab.

Pedometer. All patients will receive a pedometer with weekly step goals. The initial goal will be to walk 800 more steps than the number of steps walked during Week-12 of supervised training. Patients will be instructed to increase the number of weekly steps as recommended by Moy et al.⁹¹

Weekly Motivational Interviewing by Telephone. Motivational interviewing is a patient-centered, directive style intervention intended to enhance readiness for lifestyle change by helping patients explore and resolve ambivalence.⁹² The weekly motivational interviews by telephone will be preferably carried out by the trainer who primarily worked with the patient. The purpose of these interviews is to strengthen the patients' motivation and commitment to the program. The trainer will ask patients how often they exercised during the previous week and for how long. Patients in the breathing-retraining plus exercise group will also be asked on their use of the breathing techniques taught in the lab. If patients are not adherent to the home program, the trainer will work with them to overcome or minimize real or perceived barriers to adherence. We expect that each phone call will last about 10 min.

Monthly Booster Training Sessions. These sessions are intended to review information previously taught to the patients, to re-evaluate each patients' home program and to provide reinforcement and encouragement. During the booster sessions, patients will undergo exercise-training at the same intensity as in the last lab session. (We recognize that there may be a need to adjust the intensity of exercise in some patients.) Upon completion of exercise, staff will discuss facilitators and barriers to physical activity outside the lab. For breathing-retraining patients, the booster session will include breathing-retraining set with the same specifications as the last session completed in the lab. In these patients, the session will include a discussion to reinforce the need to practice the breathing strategies taught in the lab during activities of daily living. Based on the findings of McAuley et al,⁹³ we reason that the proposed booster

sessions will have a powerful effect on self-efficacy as they will provide information on mastery and additional motivation to the patients.

Time Summary. The two groups of patients will complete the same testing procedures at the same time intervals. During training, all patients will exercise in the laboratory for about 1 hour thrice weekly.

Treadmill Test Protocols. All treadmill tests will be separated by at least 48 hours of rest.

Incremental-Load Treadmill Test. The purpose for this test is to determine the patient's VO_{2peak} and his/her breathing pattern during exercise. This information will be used to set the workload during the constant-load treadmill test and to set the breathing-retraining goals during exercise-training. At the start of the incremental-load test the treadmill will be set at 0% grade and at a speed of 1.8 mph. Every 30 seconds during testing, the incline will increase by 0.5%. Additionally, after minute 6 of the protocol, the treadmill's speed will increase by 0.2 mph every 3 min. With this protocol, energy demands step up by one metabolic equivalent (MET)⁹⁴ every 3 min.

Constant-Load Treadmill Test. The purpose of this test is to determine exercise duration, respiratory pattern, extent of exercise-induced dynamic hyperinflation, dyspnea and leg fatigue at randomization, after 12-weeks of training and 6 and 12 months after randomization. The speed and grade of the treadmill will be the same as the speed and grade recorded when patients reached 85% of their VO_{2peak} during the baseline incremental-load treadmill test.

Recordings During Incremental-Load and Constant-Load Tests. During all treadmill tests, cardiac activity (Leads II, V1, and V5; General Electric), SpO_2 (Nellcor Works), airflow (MedGraphics). VO_2 and VCO_2 (MedGraphics) will be monitored continuously. This setup allows us to record of minute ventilation, tidal volume, and respiration rate as well as breath-by-breath recordings of gas exchange.

As previously described,^{6,7,84} VO_{2peak} will be the highest value of VO_2 recorded between the 60 sec before and 30 sec after the incremental-load treadmill exercise test ends, when patients have reached their 'peak effort'.

Inspiratory capacity will be measured just before each exercise test, every 2 min throughout the test, at peak exercise and at 2 and 4 min into recovery.⁷ Similarly, blood pressure will be recorded every 2 min. Ratings of perceived dyspnea and exertion will be obtained using Borg's ratio scale^{49,50} during the last 30 sec of each stage of exercise. For patients experiencing exercise desaturation ($SpO_2 < 90\%$), an oxygen reservoir system (100 L Douglas bag) will be used for continuous oxygen supplementation.⁷

Chronic Respiratory Disease Questionnaire (CRQ). This questionnaire is designed to determine how the lives of patients with chronic airflow limitation are affected by the illness and the perceived impact of symptoms and limitations on quality of life.¹⁰⁵ The 20 questions on the CRQ measure four dimensions: dyspnea, fatigue, emotional function, and the patient's feeling of control over the disease (mastery). Each question is scored during a structured interview. Test-retest reliability and validity of the CRQ have been established.¹⁰⁶ Patients will not be informed of their previous responses on the questionnaire when the CRQ is administered at follow-up. CRQ scores will be used as covariates in the final analysis if appropriate.

Short Form-36 Health Survey (SF-36): This is a general health-related quality of life instrument to quantify perceived physical function and mental health.^{107,108} The SF-36 will be used to describe the sample and to have a comparator measure to published clinical pulmonary rehabilitation programs.¹⁰⁹

Charlson Comorbidity Index. This validated¹¹⁰ and widely utilized index^{65,66} will be used to determine whether comorbidities influence study outcomes.

Depression and Anxiety. To control for the influence of ongoing depression and anxiety on adherence, the Center for Epidemiologic Studies Depression Scale (CES-D)¹¹¹ and the State-Trait Anxiety Inventory (STAI)¹¹²⁻¹¹⁴ will be administered at baseline and at major data collection time-periods. CES-D and STAI scores will be used as covariates in the final analysis if appropriate.

Self-Efficacy. The Self-Efficacy for Walking¹¹⁵ and the Self-Efficacy for Shortness of Breath questionnaires¹¹⁶ will be used to measure self-efficacy at all time periods.^{115,117} These are reliable and valid¹¹⁶ instruments designed to assess a patient's confidence in keeping shortness of breath from interfering from walking or from doing what they want to do.

Exacerbations. Approximately 50% of patients with moderate-severe COPD are expected to experience an exacerbation over the course of 12 months.¹⁵ Exacerbations negatively impact adherence to exercise programs and quality of life.¹⁵ Exacerbations will be monitored weekly throughout the study. Acute exacerbations are defined by changes in sputum color, volume or consistency and are accompanied by an increase in dyspnea.⁶⁰ Acute exacerbations are classified as mild (the need for increased use of inhaled bronchodilators only), moderate (the need for systemic corticosteroids and/or antibiotics), or severe (the need for hospitalization).⁶⁰ Since moderate exacerbations usually resolve in approximately two weeks,¹¹⁸

patients who experience an exacerbation within two weeks of testing will have their testing deferred until the exacerbation has resolved.

Statistical Analysis. Descriptive statistics will be used to summarize baseline characteristics of participants. Comparison of the two groups (breathing-retraining plus exercise-training and exercise-training alone) will be undertaken for all baseline variables to determine whether any imbalances on purported prognostic factors exist. T-test for two independent samples will be used for comparison of the two groups at baseline, continuous data and changes in continuous outcomes from baseline to end of treatment. The continuity-corrected chi-square test will be used to compare categorical data in the two groups at baseline and end of treatment. When this test is not appropriate due to small category frequencies, Fisher's exact test will be used. To examine the potential for response bias, baseline measurements of patients who complete and do not complete follow-up visits will be compared. This procedure will be done for the overall study sample and for each randomized group.

Primary Hypotheses:

H₁: IN PATIENTS WITH COPD, IMPROVEMENTS IN EXERCISE DURATION ON A CONSTANT-LOAD TREADMILL TEST WILL BE GREATER AFTER 12 WEEKS OF BREATHING-RETRAINING PLUS TREADMILL EXERCISE-TRAINING FOLLOWED BY A 42-WEEK ADHERENCE-INTERVENTION PROGRAM (ONE YEAR TOTAL) THAN AFTER 12 WEEKS OF TREADMILL EXERCISE-TRAINING ALONE FOLLOWED BY A 42-WEEK ADHERENCE-INTERVENTION PROGRAM (ONE YEAR TOTAL).

The principal analysis of the primary outcome measure will compare changes in duration of exercise from baseline to end of follow-up in the constant-load treadmill test using the 2-sample t-test (two-tailed $P = .05$). The primary analysis will be based on intention-to-treat principles (i.e., all randomized patients will be included in the analysis). Multiple imputation will be used for study patients who are missing the 12-month measurement. This imputation model will be based on the baseline characteristics of the study participants. The primary analysis will be repeated, restricted to patients who complete the treatment protocol. Linear regression will be used to determine whether the observed treatment persists after adjustment for baseline covariates and measures of treatment adherence. Since several measurements will be taken on each patient, mixed-models analysis will be used to compare the changes on the constant-load treadmill test over time between the two groups. The missing data pattern will be explored to determine whether data have been informatively censored. If the data do not appear to be missing at random, an indicator variable (alone and as an interaction with slope) will be used in the model to separately estimate intercepts and slopes for the censored group and the group with complete data. At the patient level, random intercepts and slopes will be assumed. Several correlation structures will be evaluated to determine which best represents the observed correlation structure. We will also use multiple imputation to estimate the missing values in the mixed-model ANOVA as a sensitivity analysis. This will be accomplished in two ways. The first multiple imputation technique will account for the treatment group to which each study participant was randomized. We will then use a second multiple imputation model in which all missing values are imputed from a model that only includes data from the control group. This latter multiple imputation model will provide a lower bound (or conservative) estimate of the treatment differences.

Secondary Hypotheses:

H₂: ONE YEAR AFTER RANDOMIZATION, REDUCTIONS IN EXERCISE-INDUCED DYNAMIC HYPERINFLATION WILL BE GREATER IN THE BREATHING-RETRAINING GROUP THAN IN THE EXERCISE-ALONE GROUP.

Statistical analysis for H₂ will parallel that of H₁.

H₃: ONE YEAR AFTER RANDOMIZATION, IMPROVEMENTS IN THE 6-MINUTE WALK DISTANCE WILL BE GREATER IN THE BREATHING-RETRAINING GROUP THAN IN THE EXERCISE-ALONE GROUP.

Statistical analysis for H₃ will parallel that of H₁.

H₄: ONE YEAR AFTER RANDOMIZATION, IMPROVEMENTS IN PERCEIVED MASTERY OVER BREATHING WILL BE GREATER IN THE BREATHING-RETRAINING GROUP THAN IN THE EXERCISE-ALONE GROUP.

Statistical analysis for H₄ will parallel that of H₁.

References

1. Marciniuk DD, Brooks D, Butcher S, et al. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease--practical issues: a Canadian Thoracic Society Clinical Practice Guideline. *Canadian respiratory journal : journal of the Canadian Thoracic Society* 2010;17:159-68.
2. Vassaux C, Torre-Bouscoulet L, Zeineldine S, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. *Eur Respir J* 2008;32:1275-82.
3. O'Donnell DE, Guenette JA, Maltais F, Webb KA. Decline of resting inspiratory capacity in COPD: the impact on breathing pattern, dyspnea, and ventilatory capacity during exercise. *Chest* 2012;141:753-62.
4. Hussain O, Collins EG, Adiguzel N, Langbein WE, Tobin MJ, Laghi F. Contrasting pressure-support ventilation and helium-oxygen during exercise in severe COPD. *Respir Med* 2011;105:494-505.
5. Collins E, Langbein W, Fehr L, et al. Can ventilation-feedback training decrease exertional dyspnea and improve exercise tolerance in patients with COPD? *Am J Respir Crit Care Med* 2003;167:A314.
6. Collins EG, Jelinek C, O'Connell S, et al. Contrasting breathing retraining and helium-oxygen during pulmonary rehabilitation in COPD: A randomized clinical trial. *Respir Med* 2013.
7. Collins EG, Langbein WE, Fehr L, et al. Can ventilation-feedback training augment exercise tolerance in patients with chronic obstructive pulmonary disease? *Am J Respir Crit Care Med* 2008;177:844-52.
8. Collins EG, Fehr L, Bammert C, et al. Effect of ventilation-feedback training on endurance and perceived breathlessness during constant work-rate leg-cycle exercise in patients with COPD. *J Rehabil Res Dev* 2003;40:35-44.
9. Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. *Am J Respir Crit Care Med* 2003;167:880-8.
10. Steele BG, Belza B, Cain KC, et al. A randomized clinical trial of an activity and exercise adherence intervention in chronic pulmonary disease. *Archives of physical medicine and rehabilitation* 2008;89:404-12.
11. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. *Annals of internal medicine* 1995;122:823-32.
12. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. *The American journal of medicine* 2000;109:207-12.
13. Heppner PS, Morgan C, Kaplan RM, Ries AL. Regular walking and long-term maintenance of outcomes after pulmonary rehabilitation. *Journal of cardiopulmonary rehabilitation* 2006;26:44-53.
14. Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. *Lancet* 2000;355:362-8.
15. Carr SJ, Goldstein RS, Brooks D. Acute exacerbations of COPD in subjects completing pulmonary rehabilitation. *Chest* 2007;132:127-34.
16. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. *Am J Respir Crit Care Med* 2006;173:1390-413.
17. Guenette JA, Webb KA, O'Donnell DE. Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD? *Eur Respir J* 2012;40:322-9.
18. Laghi F, Tobin MJ. Disorders of the Respiratory Muscles. *Am J Respir Crit Care Med* 2003;168:10-48.
19. Yan S, Kaminski D, Sliwinski P. Inspiratory muscle mechanics of patients with chronic obstructive pulmonary disease during incremental exercise. *Am J Respir Crit Care Med* 1997;156:807-13.
20. Sinderby C, Spahilja J, Beck J, et al. Diaphragm activation during exercise in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;163:1637-41.
21. Bernard S, LeBlanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;158:629-34.
22. Mostert R, Goris A, Weling-Scheepers C, Wouters EF, Schols AM. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. *Respir Med* 2000;94:859-67.
23. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2002;166:809-13.
24. Caron MA, Debigare R, Dekhuijzen PN, Maltais F. Comparative assessment of the quadriceps and the diaphragm in patients with COPD. *J Appl Physiol* 2009;107:952-61.

25. Seymour JM, Ward K, Sidhu PS, et al. Ultrasound measurement of rectus femoris cross-sectional area and the relationship with quadriceps strength in COPD. *Thorax* 2009;64:418-23.
26. Hammond K, Mampillo J, Laghi FA, et al. Validity and reliability of rectus femoris ultrasound measurements. Comparison of curved-array and linear-array transducers. *Journal of Rehabilitation Research & Development* under review.
27. Vogiatzis I, Terzis G, Stratakos G, et al. Effect of pulmonary rehabilitation on peripheral muscle fiber remodeling in patients with COPD in GOLD stages II to IV. *Chest* 2011;140:744-52.
28. Puente-Maestu L, Perez-Parra J, Godoy R, et al. Abnormal mitochondrial function in locomotor and respiratory muscles of COPD patients. *Eur Respir J* 2009;33:1045-52.
29. Flakoll P, Sharp R, Baier S, Levenhagen D, Carr C, Nissen S. Effect of beta-hydroxy-beta-methylbutyrate, arginine, and lysine supplementation on strength, functionality, body composition, and protein metabolism in elderly women. *Nutrition* 2004;20:445-51.
30. Maddocks M, Gao W, Higginson IJ, Wilcock A. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. *Cochrane database of systematic reviews* 2013;1:CD009419.
31. Gondin J, Brocca L, Bellinzona E, et al. Neuromuscular electrical stimulation training induces atypical adaptations of the human skeletal muscle phenotype: a functional and proteomic analysis. *J Appl Physiol* 2011;110:433-50.
32. Dolmage TE, Goldstein RS. Effects of one-legged exercise training of patients with COPD. *Chest* 2008;133:370-6.
33. Celli B. The importance of exercise training in pulmonary rehabilitation. In: Weisman I, Zaballos R, eds. *Progress in Respiratory Research Clinical Exercise Testing*. Basel: Karger; 2002.
34. Mador MJ, Krawza M, Alhajhusian A, Khan AI, Shaffer M, Kufel TJ. Interval training versus continuous training in patients with chronic obstructive pulmonary disease. *J Cardiopulm Rehabil Prev* 2009;29:126-32.
35. Varga J, Porszasz J, Boda K, Casaburi R, Somfay A. Supervised high intensity continuous and interval training vs. self-paced training in COPD. *Respir Med* 2007;101:2297-304.
36. Beauchamp MK, Nonoyama M, Goldstein RS, et al. Interval versus continuous training in individuals with chronic obstructive pulmonary disease--a systematic review. *Thorax* 2010;65:157-64.
37. Faager G, Stahle A, Larsen FF. Influence of spontaneous pursed lips breathing on walking endurance and oxygen saturation in patients with moderate to severe chronic obstructive pulmonary disease. *Clinical rehabilitation* 2008;22:675-83.
38. Faling LJ. Controlled breathing techniques and chest physical therapy in chronic obstructive pulmonary disease and allied conditions. In: Casaburi R, Petty TL, eds. *Principles and Practice of Pulmonary Rehabilitation*. Philadelphia: W.B. Saunders; 2003:167-82.
39. Jones AY, Dean E, Chow CCS. Comparison of the oxygen cost of breathing exercise and spontaneous breathing in patients with stable chronic obstructive pulmonary disease. *Phys Ther* 2003;83:424-31.
40. Petty TL, Guthrie A. The effects of augmented breathing maneuvers on ventilation in severe chronic airway obstruction. *Respiratory care* 1971;16:104-11.
41. Mueller RE, Petty TL, Filley GF. Ventilation and arterial blood gas changes induced by pursed lips breathing. *J Appl Physiol* 1970;28:784-9.
42. Nield MA, Soo Hoo GW, Roper JM, Santiago S. Efficacy of pursed-lips breathing: a breathing pattern retraining strategy for dyspnea reduction. *J Cardiopulm Rehabil Prev* 2007;27:237-44.
43. Byrne C, Twist C, Eston R. Neuromuscular function after exercise-induced muscle damage: theoretical and applied implications. *Sports medicine* 2004;34:49-69.
44. McNicol AJ, O'Brien BJ, Paton CD, Knez WL. The effects of increased absolute training intensity on adaptations to endurance exercise training. *Journal of science and medicine in sport / Sports Medicine Australia* 2009;12:485-9.
45. Burtin C, Saey D, Saglam M, et al. Effectiveness of exercise training in patients with COPD: the role of muscle fatigue. *Eur Respir J* 2012;40:338-44.
46. Amann M, Regan MS, Kobitany M, et al. Impact of pulmonary system limitations on locomotor muscle fatigue in patients with COPD. *American journal of physiology Regulatory, integrative and comparative physiology* 2010;299:R314-24.
47. Dempsey JA, Romer L, Rodman J, Miller J, Smith C. Consequences of exercise-induced respiratory muscle work. *Respiratory physiology & neurobiology* 2006;151:242-50.
48. Stark-Leyva KN, Beck KC, Johnson BD. Influence of expiratory loading and hyperinflation on cardiac output during exercise. *J Appl Physiol* 2004;96:1920-7.

49. Saey D, Debigare R, LeBlanc P, et al. Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2003;168:425-30.
50. Butcher SJ, Lagerquist O, Marciniuk DD, Petersen SR, Collins DF, Jones RL. Relationship between ventilatory constraint and muscle fatigue during exercise in COPD. *Eur Respir J* 2009;33:763-70.
51. Fan VS, Giardino ND, Blough DK, Kaplan RM, Ramsey SD, Nett Research G. Costs of pulmonary rehabilitation and predictors of adherence in the National Emphysema Treatment Trial. *COPD* 2008;5:105-16.
52. Baltzan MA, Scott AS, Wolkove N, et al. Fatigue in COPD: prevalence and effect on outcomes in pulmonary rehabilitation. *Chronic respiratory disease* 2011;8:119-28.
53. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *The New England journal of medicine* 2010;363:1128-38.
54. Hoyert DL, Xu JQ. Deaths: Preliminary data for 2011. US Department of Health and Human Services. Hyattsville, MD: Centers for Disease Control and Prevention; 2011.
55. Common chronic conditions among VA patients: Age, gender, mortality, utilization, and average annual cost per patient in fiscal year 2010. Department of Veterans Affairs, 2012. (Accessed November 23, 2012, 2012).
56. Centers for Disease C, Prevention. Chronic obstructive pulmonary disease among adults - United States, 2011. *MMWR Morbidity and mortality weekly report* 2012;61:938-43.
57. Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P. The impact of chronic obstructive pulmonary disease on work loss in the United States. *Am J Respir Crit Care Med* 2002;165:704-7.
58. Burgel PR, Escamilla R, Perez T, et al. Impact of comorbidities on COPD-specific health-related quality of life. *Respir Med* 2012.
59. Solanes I, Guell R, Casan P, et al. Duration of pulmonary rehabilitation to achieve a plateau in quality of life and walk test in COPD. *Respir Med* 2009;103:722-8.
60. Bourbeau J, Tan WC, Benedetti A, et al. Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD. *COPD* 2012.
61. Laghi F, Jubran A, Topeli A, et al. Effect of lung volume reduction surgery on diaphragmatic neuromechanical coupling at 2 years. *Chest* 2004;125:2188-95.
62. Laghi F, Jubran A, Topeli A, et al. Effect of lung volume reduction surgery on neuromechanical coupling of the diaphragm. *Am J Respir Crit Care Med* 1998;157:475-83.
63. Hatipoglu U, Laghi F, Tobin MJ. Does inhaled albuterol improve diaphragmatic contractility in patients with chronic obstructive pulmonary disease? *Am J Respir Crit Care Med* 1999;160:1916-21.
64. Laghi F, Langbein WE, Jaeger RJ, et al. Can electrical stimulation of abdominal muscles assist cough in patients with spinal cord injury? *Am J Respir Crit Care Med* 2003;167:A416.
65. Collins EG, Halabi S, Langston M, Schnell T, Tobin MJ, Laghi F. Sexual dysfunction in men with COPD: impact on quality of life and survival. *Lung* 2012;190:545-56.
66. Halabi S, Collins EG, Thorevska N, Tobin MJ, Laghi F. Relationship between depressive symptoms and hypogonadism in men with COPD. *COPD* 2011;8:346-53.
67. Laghi F, Antonescu-Turcu A, Collins E, et al. Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. *Am J Respir Crit Care Med* 2005;171:728-33.
68. Topeli A, Laghi F, Tobin MJ. The voluntary drive to breathe is not decreased in hypercapnic patients with severe COPD. *Eur Respir J* 2001;18:53-60.
69. Collins EG, McBurney C, Butler J, et al. The Effects of Walking or Walking-with-Poles Training on Tissue Oxygenation in Patients with Peripheral Arterial Disease. *International journal of vascular medicine* 2012;2012:985025.
70. Laghi F, Langbein W, Antonescu-Turcu A, Jubran A, Bammert C, Tobin M. Respiratory and skeletal muscles in hypogonadal men with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;171:598-605.
71. Collins EG, Langbein WE, Fehr L, et al. Treadmill versus cycle ergometry testing in COPD [abstract]. *Am J Respir Crit Care Med* 2004;169:A771.
72. Collins EG, O'Connell S, McBurney C, et al. Comparison of walking with poles and traditional walking for peripheral arterial disease rehabilitation. *J Cardiopulm Rehabil Prev* 2012;32:210-8.
73. Collins EG, Langbein WE, Orebaugh C, et al. Polestriding exercise and vitamin E for management of peripheral vascular disease. *Medicine and science in sports and exercise* 2003;35:384-93.
74. Butler JA, Miller T, O'Connell S, Jelinek C, Collins EG. Physical activity inventory for patients with SCI. *Journal of Spinal Cord Injury Nursing* 2008;25:20-8.

75. Sherry D, Knight BP, Casey C, et al. Daily physical activity with cardiac resynchronization therapy. *Biological Research in Nursing* in press.
76. Jubran A, Lawm G, Kelly J, et al. Depressive disorders during weaning from prolonged mechanical ventilation. *Intensive Care Med* 2010;36:828-35.
77. Jubran A, Lawm G, Duffner LA, et al. Post-traumatic stress disorder after weaning from prolonged mechanical ventilation. *Intensive Care Med* 2010;36:2030-7.
78. Topeli A, Laghi F, Tobin MJ. Effect of closed unit policy and appointing an intensivist in a developing country. *Critical care medicine* 2005;33:299-306.
79. Jubran A, Grant BJ, Duffner LA, et al. Effect of pressure support vs unassisted breathing through a tracheostomy collar on weaning duration in patients requiring prolonged mechanical ventilation: a randomized trial. *JAMA* 2013;309:671-7.
80. Collins E, Langbein WE, Dilan-Koetje J, et al. Effects of exercise training on aerobic capacity and quality of life in individuals with heart failure. *Heart Lung* 2004;33:154-61.
81. Collins EG, Edwin Langbein W, Orebaugh C, et al. PoleStriding exercise and vitamin E for management of peripheral vascular disease. *Medicine and science in sports and exercise* 2003;35:384-93.
82. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. *Eur Respir J* 2004;23:832-40.
83. Rikli RE, Jones JJ. Assessing physical performance in independent older adults: Issues and guidelines. *J of Aging and Physical Activity* 1997;5:244-61.
84. Collins EG. Reducing Dynamic Hyperinflation Through Breathing Retraining. Edward Hines Jr., VA Hospital: Rehabilitation Research & Development, Department of Veterans Affairs; 2009.
85. Egan C, Deering BM, Blake C, et al. Short term and long term effects of pulmonary rehabilitation on physical activity in COPD. *Respir Med* 2012;106:1671-9.
86. Covey MK. Nurse managed: Sequential resistance training followed by aerobic training in COPD. University of Illinois at Chicago and Edward Hines Jr., VA Hospital: NINR; 2008.
87. Covey MK, McAuley E, Kapella MC, et al. Upper-body resistance training and self-efficacy enhancement in COPD. *Journal of Pulmonary and Respiratory Medicine* 2012;S:1-8.
88. Borg GV. Psychophysical bases of perceived exertion. *Medicine and science in sports and exercise* 1982;14:377-87.
89. Earnest CP. Exercise interval training: An improved stimulus for improving the physiology of pre-diabetes. *Med Hypotheses* 2008.
90. Collins EG. Effect of Ventilation-Feedback Training on Exercise Performance in COPD. Edward Hines Jr., VA Hospital: Rehabilitation Research and Development, Department of Veterans Affairs; 2000.
91. Moy ML, Janney AW, Nguyen HQ, et al. Use of pedometer and Internet-mediated walking program in patients with chronic obstructive pulmonary disease. *J Rehabil Res Dev* 2010;47:485-96.
92. Miller WR, Rollnick S. Motivational interviewing, Third Edition: Helping people change. New York: Guilford Press; 2013.
93. McAuley E, Lox C, Duncan TE. Long-term maintenance of exercise, self-efficacy, and physiological change in older adults. *J Gerontol* 1993;48:P218-24.
94. Kenny WL, Humphrey RH, Bryant CX, et al. ACSM's Guidelines for exercise testing and prescription, 5th ed. Baltimore: Williams & Wilkins; 1995.
95. Weisman IM, Zebalows RJ. An integrative approach to the interpretation of cardiopulmonary exercise testing. In: Weisman IM, Zebalows RJ, eds. *Clinical Exercise Testing Progress in Respiratory Research*. Basel: Karger; 2002:300-22.
96. Baraun NMT, Arora NS, Rochester DF. Force-length relationship of the normal human diaphragm. *J Appl Physiol* 1982;53:405-12.
97. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. *The American review of respiratory disease* 1969;99:696-702.
98. Larson J, Covey M, Berry J, Wirtz S, Alex C, Matsuo M. Discontinuous incremental threshold loading test measure of respiratory muscle endurance in patients with COPD. *Chest* 1999;115:60-7.
99. Mador MJ, Mogri M, Patel A. Contractile Fatigue of the Quadriceps Muscle Predicts Improvement in Exercise Performance After Pulmonary Rehabilitation. *J Cardiopulm Rehabil Prev* 2013.
100. Symons TB, Vandervoort AA, Rice CL, Overend TJ, Marsh GD. Effects of maximal isometric and isokinetic resistance training on strength and functional mobility in older adults. *J Gerontol A Biol Sci Med Sci* 2005;60:777-81.

101. Symons TB, Vandervoort AA, Rice CL, Overend TJ, Marsh GD. Reliability of a single-session isokinetic and isometric strength measurement protocol in older men. *J Gerontol A Biol Sci Med Sci* 2005;60:114-9.
102. American Thoracic Society. ATS Statement: Guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002;166:111-7.
103. Hill K, Dolmage TE, Woon L, Goldstein R, Brooks D. Measurement properties of the SenseWear armband in adults with chronic obstructive pulmonary disease. *Thorax* 2010;65:486-91.
104. Troosters T, Sciruba F, Battaglia S, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. *Respir Med* 2010;104:1005-11.
105. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. *Thorax* 1987;42:773-8.
106. Guyatt GH. The Chronic Respiratory Questionnaire: Background information and interviewing suggestions. McMaster University, Canada 1986.
107. www.qualitymetric.com/demos/SF-36v2.html. 2003. (Accessed May 24, 2003, 2003,
108. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. *Chest* 2007;131:4S-42S.
109. Spruit MA, Singh SJ, Garvey C, et al. Concepts and Advances in Pulmonary Rehabilitation. Based on the Official 2012 American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. *Am J Respir Crit Care Med* 2013;188:e13-64.
110. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. *J Clin Epidemiol* 1994;47:1245-51.
111. Burnam MA, Wells KB, Leaske B, Landsverk J. Development of a brief screening instrument for detecting depressive disorders. *Medical care* 1988;26:775-89.
112. Spielberger CD, Gorsuch RL, Lushene RE. Manual for State-Trait Anxiety Inventory. Palo Alto 1970.
113. Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. *Chest* 2005;127:1205-11.
114. Okun A, Stein RE, Bauman LJ, Silver EJ. Content validity of the Psychiatric Symptom Index, CES-depression Scale, and State-Trait Anxiety Inventory from the perspective of DSM-IV. *Psychological reports* 1996;79:1059-69.
115. Kaplan RM, Atkins CJ, Reinsch S. Specific efficacy expectations mediate exercise compliance in patients with COPD. *Health psychology : official journal of the Division of Health Psychology, American Psychological Association* 1984;3:223-42.
116. Lorig K, Stewart AL, Ritter P, Gonzalez V, Laurent D, Lynch J. Outcome measures for health education and other health care interventions. Thousand Oaks, CA: Sage Publications; 1996.
117. Kaplan RM, Ries AL, Prewitt LM, Eakin E. Self-efficacy expectations predict survival for patients with chronic obstructive pulmonary disease. *Health psychology : official journal of the Division of Health Psychology, American Psychological Association* 1994;13:366-8.
118. Seemungal T, Donaldson G, Bhowmik A, Jeffries D, Wedzicha J. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;161:1608-13.
119. Bellg AJ, Borrelli B, Resnick B, et al. Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the NIH Behavior Change Consortium. *Health psychology : official journal of the Division of Health Psychology, American Psychological Association* 2004;23:443-51.
120. Heerema-Poelman A, Stuive I, Wempe JB. Adherence to a Maintenance Exercise Program 1 Year After Pulmonary Rehabilitation: WHAT ARE THE PREDICTORS OF DROPOUT? *J Cardiopulm Rehabil Prev* 2013;33:419-26.
121. Norweg A, Collins EG. Evidence for cognitive-behavioral strategies improving dyspnea and related distress in COPD. *International journal of chronic obstructive pulmonary disease* 2013;8:439-51.
122. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. *PLoS one* 2012;7:e37483.
123. Vivodtzev I, Debigare R, Gagnon P, et al. Functional and muscular effects of neuromuscular electrical stimulation in patients with severe COPD: a randomized clinical trial. *Chest* 2012;141:716-25.